Noninvasive Follicular Thyroid Neoplasia With Papillary‐Like Nuclear Characteristics (NIFTP): Clinico‐Pathological Analysis in a Chilean Centre
Authors' conclusion
In this series, NIFTP showed indolent behaviour and excellent prognosis. Ultrasonographically, 90% presented as ACR-TIRADS 3 or 4, with less than 10% as ACR-TIRADS 5. Regarding FNAB, nearly half were indeterminate, one-third were Bethesda V, and none Bethesda VI. No significant differences in clinical outcomes were found between lobectomy and TT.
Study context
- Population
- Patients with NIFTP treated with surgery at a Chilean centre, 2016–2023of 1103 operated
- Participants
- 104 patients
- Outcome
- Response to treatment (low-risk differentiated thyroid cancer (DTC) criteria), followed ≥1 year
- Follow-up
- ≥ 1 year
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
- Followed ≥1 year
- 52 (54%)
- Excellent response
- 34 (65%)
- Indeterminate response
- 15 (28.8%)
- Incomplete biochemical response
- 3 (5.7%)
- Incomplete structural response
- 0
- Deaths at end of follow-up
- 0
- New interventions for recurrence
- 0
Observational data: associations, not effects.
Further findings
Incidental vs Non-incidental
Tumour size, incidental vs non-incidental NIFTP · smaller with incidental
P < 0.001
- Tumour size, incidental vs non-incidental NIFTP — Incidental NIFTP
- 16 (15%)
Bethesda II vs Other Bethesda
Tumour size, Bethesda II vs other Bethesda categories · larger with Bethesda II · surgery in Bethesda II indicated for nodule growth
P = 0.015
Baseline characteristics
- Female
- 85 (81.7%)
- Age, years
- 44 ± 14.2
- Median tumour size
- 1.7 cm (range 0.1-7.1)
- Multifocal
- 12 (11.5%)
- Bilateral
- 5 (4.8%)
ACR-TIRADS on preoperative US (86 available)
- ACR-TIRADS 2
- 1 (1.2%)
- ACR-TIRADS 3
- 39 (45.3%)
- ACR-TIRADS 4
- 38 (44.2%)
- ACR-TIRADS 5
- 8 (9.3%)
Bethesda category of fine-needle aspiration biopsy (FNAB) (86 available)
- Bethesda I
- 2 (2.3%)
- Bethesda II
- 10 (11.6%)
- Bethesda III
- 20 (23.3%)
- Bethesda IV
- 24 (27.9%)
- Bethesda V
- 30 (34.9%)
Type of surgery
- Lobectomy
- 43 (41.3%)
- Total thyroidectomy
- 58 (55.8%)
- Total thyroidectomy (TT) and lymph node dissection
- 3 (2.9%)
- No significant differences between lobectomy and TT in sex, ACR-TIRADS, tumour size or ThyroidPrint® results
ThyroidPrint® in Bethesda III or IV
- Tested
- 12
- Suspicious
- 11 (92%)
- Suspicious who underwent lobectomy
- 8 (67%)
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →